Register Login

Stoke Therapeutics (STOK)

(10% Negative) Stoke Therapeutics (STOK) Announces Delay in patients Trials for Dravet syndrome Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8:47 p.m.

    📋 Stoke Therapeutics (STOK) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:34:29

    Event Type: Clinical Trial Update

    Event Details:

    Stoke Therapeutics (STOK) Announces Clinical Trial Update Stoke Therapeutics (STOK) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: patients, treatment
    • Diseases/Conditions: Dravet syndrome, expedited development
    • Clinical Stage: Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: the Completion of Enrollment
    • Updated Timeline: Q2 2026
      • expected in the second quarter of 2026

    🔬 Clinical Development Pipeline (Stoke Therapeutics):

    Product Type Development Stage Therapeutic Area Source
    zorevunersen DRUG Phase PHASE3 Dravet Syndrome ClinicalTrials.gov
    SLV-154 DRUG Phase PHASE1 Squamous Cell Cancer of Head and Neck (SCCHN) ClinicalTrials.gov
    Sham Comparator OTHER Phase PHASE3 Dravet Syndrome ClinicalTrials.gov
    SLV-324 intravenous (IV infusion) DRUG Phase PHASE1 Metastatic Solid Tumors ClinicalTrials.gov
    radiotherapy RADIATION Phase PHASE1 Solid Tumor Cancer ClinicalTrials.gov
    WTX212A injection DRUG Phase PHASE1 Solid Tumor Cancer ClinicalTrials.gov
    STK-001 DRUG Phase PHASE2 Dravet Syndrome ClinicalTrials.gov
    PAZ320 DRUG Phase PHASE2 Type 2 Diabetes Treated With Insulin ClinicalTrials.gov
    Placebo Oral Tablet DRUG Approved Type 2 Diabetes Mellitus ClinicalTrials.gov
    Placebo OTHER Phase PHASE2 Type2 Diabetes Mellitus ClinicalTrials.gov
    BTI320 DRUG Phase PHASE2 Type2 Diabetes Mellitus ClinicalTrials.gov
    WTX221 DRUG Phase EARLY_PHASE1 Gout Tophus ClinicalTrials.gov
    PD -1/PD-L1 monoclonal antibody DRUG Phase EARLY_PHASE1 Advanced Lung Cancer ClinicalTrials.gov
    Engineered erythrocytes (or red blood cells) covalently conjugated with commercially available anti-PD-1 antibodies on their membranes DRUG Phase PHASE1 Cancer ClinicalTrials.gov
    engineered red blood cell DRUG Phase EARLY_PHASE1 Cancer ClinicalTrials.gov
    STK-001 - Multiple Ascending Doses DRUG Phase PHASE1 Dravet Syndrome ClinicalTrials.gov
    STK-001 - Single Ascending Doses DRUG Phase PHASE1 Dravet Syndrome ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Stoke Therapeutics
    • Ticker Symbol: STOK

Search

News categories